Inxmed co. ltd
WebPrivate. InxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma …
Inxmed co. ltd
Did you know?
WebPhone Number +0086-21-50630108. InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options … WebI am the co-founder & CEO of In-Med Prognostics Inc, an AI/ML firm operating in healthcare, wellness, and sports tech space. Our proven capabilities are in translational …
WebInxMed Co., Ltd (InxMed) is a Pharmaceutical Company located in Shanghai China, Asia, and was founded in 2024. Request Profile Update Download Data Home Profiles … Web30 mei 2024 · InxMed Co., Ltd is pleased to announce that the clinical data from an open-label phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and …
Web9 mei 2024 · NANJING, China, May 8, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting … Web6 apr. 2024 · GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious …
Web16 aug. 2024 · NANJING, China, Aug. 15, 2024 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing …
Web8 sep. 2024 · InxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma … pool mechanicals rackWebNANJING, China, April 14, 2024 -- InxMed Co., Ltd. announced that IN10018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy … pool mechanical roomWebInxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and … share chat inlandWebNANJING, China, May 9, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments. 14 sharechat installWeb18 okt. 2024 · InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, … sharechat in kannadaWeb20 dec. 2024 · 这是应世生物首个获得NMPA临床试验许可的创新药物，此前IN10018已于2024年8月30日获得美国FDA临床试验许可。. 应世生物创始人兼CEO王在琪博士表 … sharechat iconWeb14 apr. 2024 · InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China … share chat install play store